in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance.
.
.
.
cancer patients� lives are being put at risk because savage tory cuts to the nhs are delaying the start of their treatment by 18 months.
.
.
. 0
.
.
harvard medical school: "cgrp: a new era for migraine treatment."
.
.
.
0
.
.
.